PT  - JOURNAL ARTICLE
AU  - Fátima Virgínia Gama Justi
AU  - Gabriella Araújo Matos
AU  - Juan de Sá Roriz Caminha
AU  - Cássia Rodrigues Roque
AU  - Edinilton Muniz Carvalho
AU  - Márcio Wilker Soares Campelo
AU  - Ludmila Belayev
AU  - Luiz Gonzaga de França Lopes
AU  - Reinaldo Barreto Oriá
TI  - The Role of Ruthenium Compounds in Neurologic Diseases: A Minireview
AID  - 10.1124/jpet.121.000798
DP  - 2022 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 47--53
VI  - 380
IP  - 1
4099  - http://jpet.aspetjournals.org/content/380/1/47.short
4100  - http://jpet.aspetjournals.org/content/380/1/47.full
SO  - J Pharmacol Exp Ther2022 Jan 01; 380
AB  - Ruthenium compounds, nitric oxide donors in biologic systems, have emerged as a promising therapeutic alternative to conventional drugs in anticancer chemotherapy and as a potential neuroprotective agent with fewer cytotoxic effects. This minireview summarizes promising studies with ruthenium complexes and their roles in cancer, neuroinflammation, neurovascular, and neurodegenerative diseases. The up-to-date evidence supports that ruthenium-based compounds have beneficial effects against gliomas and other types of brain cancers, reduce motor symptoms in models of cerebral ischemia-reperfusion, and may act in the control of nociceptive and inflammatory events, such as those seen in early Alzheimer’s disease. More studies are needed to fill many current knowledge gaps about the intricate and complex biologic effects and therapeutic-related mechanisms of ruthenium, stimulating further research.SIGNIFICANCE STATEMENT This minireview summarizes studies addressing the role of ruthenium compounds on neurological illnesses, focusing on brain cancer and neurovascular and neurodegenerative diseases. No such review is available in the literature.